Skip to main
ZURA

ZURA Stock Forecast & Price Target

ZURA Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 40%
Buy 40%
Hold 20%
Sell 0%
Strong Sell 0%

Bulls say

Zura Bio Ltd has shown a significant upward movement in stock price during the third quarter, propelled by a competitor's failure to meet key study endpoints, indicating potential market share opportunities. The company is actively advancing its clinical-stage assets, with $42.1 million allocated to research and development this year, reflecting a commitment to validating the efficacy and safety of its pipeline therapies. Additionally, the upcoming increase in diagnoses of autoimmune and inflammatory diseases supports a promising market landscape, which could enhance the demand for Zura Bio's innovative treatment solutions.

Bears say

Zura Bio faces significant challenges with its asset efficacy profiles, as current trials indicate that its candidates, particularly in comparison to established treatments, may demonstrate weaker performance in key therapeutic areas. The historical underperformance of similar treatments, such as Cosentyx, further exacerbates concerns around market acceptance and potential revenue generation due to poor market uptake linked to safety warnings. Additionally, while general and administrative expenses have decreased, this reduction may not sufficiently mitigate the financial risks associated with the company's development pipeline and the doubtful efficacy of its leading assets.

ZURA has been analyzed by 5 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 40% recommend Buy, 20% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Zura Bio Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Zura Bio Ltd (ZURA) Forecast

Analysts have given ZURA a Buy based on their latest research and market trends.

According to 5 analysts, ZURA has a Buy consensus rating as of Apr 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Zura Bio Ltd (ZURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.